AXL and TYRO3 signaling pathways as therapeutic targets in bladder cancer: preclinical study

Medicine & Life Sciences

1. Urinary Bladder Neoplasms 100%
2. Kazakhstan 45%
3. Drug Repositioning 13%
4. Organoids 13%
5. Therapeutics 11%
6. Preliminary Data 10%
7. Receptor Protein-Tyrosine Kinases 10%
8. Mortality 10%
9. Life Expectancy 9%
10. Tyrosine 9%
11. Organizations 8%
12. Cell Differentiation 8%
13. Cause of Death 7%
14. Urine 7%
15. Clinical Trials 6%
16. Biomarkers 6%
17. Neoplasms 6%
18. Cell Line 5%
19. Organized Financing 5%